CD8A and neoplasm: Whereas EGCG did not change the number of tumor-infiltrating CD8+ cells compared to control tumors, the anti-PD-1 antibody treatment induced a considerable increase in CD8+ cells in the TME (Figure 4C) without affecting PD-L1 expression in the surrounding tumor cells (Figure 4D).